A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis

CONCLUSION: Although benralizumab did not meet the primary efficacy endpoint, reductions of nasal polyp scores were seen in the benralizumab group compared with the placebo group over the whole study period, especially in patients with high levels of blood eosinophils.PMID:33840229 | DOI:10.1177/19458924211009429

Source: American Journal of Rhinology and Allergy - April 12, 2021 Category: ENT & OMF Authors: Tetsuji Takabayashi Daiya Asaka Yoshitaka Okamoto Tetsuo Himi Shinichi Haruna Naohiro Yoshida Kenji Kondo Mamoru Yoshikawa Yasunori Sakuma Kunihiko Shibata Motohiko Suzuki Masayoshi Kobayashi Ryo Kawata Kenzo Tsuzuki Mitsuhiro Okano Takaya Higaki Sachio T Source Type: research